We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca's (AZN) Imfinzi Improves Survival in SCLC Study
Read MoreHide Full Article
AstraZeneca (AZN - Free Report) announced positive data from the phase III ADRIATIC study, which evaluated its blockbuster cancer drug, Imfinzi (durvalumab), for treating patients with limited-stage small cell lung cancer (LS-SCLC), an aggressive form of lung cancer.
The dual primary endpoints of this global phase III study are overall survival (OS) and progression-free survival (PFS).
Data from the study showed that treatment with Imfinzi led to statistically significant and clinically meaningful improvement in the OS and PFS in patients with LS-SCLC whose disease has not progressed after treatment with concurrent chemoradiotherapy (cCRT) versus placebo following cCRT.
Imfinzi has now become the first and only immunotherapy to demonstrate survival benefit in the LS-SCLC setting in a phase III study.
Imfinzi is already approved for the treatment of extensive-stage SCLC (ES-SCLC) in the United States, European Union, Japan, China and several other countries across the world. The approval in the ES-SCLC setting was based on data from the phase III CASPIAN study.
Shares of AstraZeneca have remained flat year to date compared with the industry’s rise of 13.1%.
Image Source: Zacks Investment Research
Notably, Imfinzi is the global standard of care in the curative-intent setting of unresectable, Stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after CRT.
Imfinzi is also approved for various other cancer indications in different settings across the world. The drug is a key revenue driver for AZN’s oncology portfolio.
The drug generated sales of $4.2 billion in 2023, up 55% year over year, driven by increased use in recent launches like gastrointestinal, biliary tract and hepatocellular carcinoma cancers and stable growth in established indications like SCLC and Stage III NSCLC.
AstraZeneca is focused on strengthening its oncology business. The company is constantly working to further strengthen this portfolio through label expansions of existing cancer drugs and advancing oncology pipeline candidates.
Zacks Rank & Stocks to Consider
AstraZeneca currently carries a Zacks Rank #3 (Hold).
In the past 60 days, estimates for ADMA Biologics’ 2024 earnings per share have improved from 22 cents to 30 cents. Year to date, shares of ADMA have rallied 38.9%.
ADMA’s earnings beat estimates in three of the trailing four quarters and met the same once, the average surprise being 85.00%.
In the past 60 days, estimates for Ligand’s 2024 earnings per share have improved from $4.42 to $4.56. Year to date, shares of LGND have gained 9.2%.
Earnings of LGND beat estimates in each of the trailing four quarters, the average surprise being 84.81%.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have improved from $4.06 to $4.43. Year to date, shares of ANIP have soared 23.2%.
Earnings of ANIP beat estimates in each of the trailing four quarters, the average surprise being 109.06%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AstraZeneca's (AZN) Imfinzi Improves Survival in SCLC Study
AstraZeneca (AZN - Free Report) announced positive data from the phase III ADRIATIC study, which evaluated its blockbuster cancer drug, Imfinzi (durvalumab), for treating patients with limited-stage small cell lung cancer (LS-SCLC), an aggressive form of lung cancer.
The dual primary endpoints of this global phase III study are overall survival (OS) and progression-free survival (PFS).
Data from the study showed that treatment with Imfinzi led to statistically significant and clinically meaningful improvement in the OS and PFS in patients with LS-SCLC whose disease has not progressed after treatment with concurrent chemoradiotherapy (cCRT) versus placebo following cCRT.
Imfinzi has now become the first and only immunotherapy to demonstrate survival benefit in the LS-SCLC setting in a phase III study.
Imfinzi is already approved for the treatment of extensive-stage SCLC (ES-SCLC) in the United States, European Union, Japan, China and several other countries across the world. The approval in the ES-SCLC setting was based on data from the phase III CASPIAN study.
Shares of AstraZeneca have remained flat year to date compared with the industry’s rise of 13.1%.
Image Source: Zacks Investment Research
Notably, Imfinzi is the global standard of care in the curative-intent setting of unresectable, Stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after CRT.
Imfinzi is also approved for various other cancer indications in different settings across the world. The drug is a key revenue driver for AZN’s oncology portfolio.
The drug generated sales of $4.2 billion in 2023, up 55% year over year, driven by increased use in recent launches like gastrointestinal, biliary tract and hepatocellular carcinoma cancers and stable growth in established indications like SCLC and Stage III NSCLC.
AstraZeneca is focused on strengthening its oncology business. The company is constantly working to further strengthen this portfolio through label expansions of existing cancer drugs and advancing oncology pipeline candidates.
Zacks Rank & Stocks to Consider
AstraZeneca currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare sector are ADMA Biologics, Inc. (ADMA - Free Report) , Ligand Pharmaceuticals Incorporated (LGND - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) , each flaunting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for ADMA Biologics’ 2024 earnings per share have improved from 22 cents to 30 cents. Year to date, shares of ADMA have rallied 38.9%.
ADMA’s earnings beat estimates in three of the trailing four quarters and met the same once, the average surprise being 85.00%.
In the past 60 days, estimates for Ligand’s 2024 earnings per share have improved from $4.42 to $4.56. Year to date, shares of LGND have gained 9.2%.
Earnings of LGND beat estimates in each of the trailing four quarters, the average surprise being 84.81%.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have improved from $4.06 to $4.43. Year to date, shares of ANIP have soared 23.2%.
Earnings of ANIP beat estimates in each of the trailing four quarters, the average surprise being 109.06%.